NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: AnaSpec, Inc.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Highlights SensoLyte® 520 Renin Assays for Human, Mouse & Rat Specific - AnaSpec, EGT Group, the provider of the ultra-sensitive SensoLyte® 520 Human Renin Assay Kit also provides renin kits specific for mouse and rat - the
SensoLyte® 520 Mouse Renin Assay Kit and SensoLyte® 520 Rat Renin Assay Kit
AnaSpec Highlights SensoLyte® 520 Renin Assays for Human, Mouse & Rat Specific

 

NewswireToday - /newswire/ - Fremont, CA, United States, 2012/04/09 - AnaSpec, EGT Group, the provider of the ultra-sensitive SensoLyte® 520 Human Renin Assay Kit also provides renin kits specific for mouse and rat - the SensoLyte® 520 Mouse Renin Assay Kit and SensoLyte® 520 Rat Renin Assay Kit.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Using our proprietary 5-FAM/QXL™ 520 fluorescence resonance energy transfer (FRET) peptide, all three assays are ideal for screening of renin inhibitors and for continuous assay of renin activity, especially for high throughput screening (HTS) purposes. In the intact FRET peptide, the fluorescence of 5-FAM is quenched by QXL™ 520. However, upon cleavage into two separate fragments by rat renin, the fluorescence of 5-FAM is recovered, and can be monitored at excitation/emission = 490/520 nm. With a high fluorescence quantum yield and long emission wavelength, the signal of 5-FAM can be detected with less interference from the autofluorescence of cell components and test compounds. The assays are performed in a convenient 96-well microplate format and can be adjusted to 384-well microplate format.

The renin–angiotensin system (RAS) plays a central role in the regulation of blood pressure and electrolyte homoeostasis.1 At the first and rate-limiting step of the RAS cascade, renin, a highly specific aspartyl protease, cleaves angiotensinogen, produced in the liver, to yield angiotensin I, which is further converted into angiotensin II by ACE (Angiotensin Converting Enzyme). Angiotensin II constricts blood vessels leading to increased blood pressure. It also increases the secretion of ADH and aldosterone, and stimulates the hypothalamus to activate the thirst reflex. Since an overactive renin-angiotensin system leads to hypertension, renin is an attractive target for the treatment of this disease. 2-4

References:
1. He, FJ. and GA. MacGregor, J. Renin Angiotensin Aldosterone Syst. 4, 11 (2003).
2. Wood, JM. et al., Hypertension, 7, 797 (1985).
3. Shibasaki, M. et al., Am. J. Hypertens. 4, 932 (1991).
4. Wood, JM.et al., Biochem. Biophys. Res. Comm. 308, 698 (2003).

For more information, please visit anaspec.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Highlights SensoLyte® 520 Renin Assays for Human, Mouse & Rat Specific

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Tiffany Kao - AnaSpec.com 
510-791-9560
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe Finds Frost & Sullivan
Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease
Exelixis and Ipsen Announce Cabozantinib in Combination with An Immune Checkpoint Inhibitor Significantly Improved Progression
Ipsen Opts-in to Join Exelixis with Ongoing Development of Cabometyx® for People Living with A Form of Thyroid Cancer
Antibiotic Alternatives Stimulate New Product Development in Global Animal Feed Ingredient Market Finds Frost & Sullivan
Health Tech Company Hologram Sciences Launches Personalized Health & Nutrition Innovation with 0 Million Backing
DSM Acquires Flavor & Fragrance Bio-based Intermediates Business from Amyris
Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination with Opdivo®
DSM and Industry Partners Launch Coalition to Close the Loop on Dyneema® - The World’s Strongest Fiber™
Pharmactive Earns Acclaim from Frost & Sullivan for Helping People Improve their Cognitive Functions with its Saffron-based Ingredient, Affron®
Tergus Lauded by Frost & Sullivan for its Full-spectrum CRO Services for Therapeutics in Dermatology
Sunquest Lauded by Frost & Sullivan for Driving Efficiency and Compliance with its Differentiated Molecular Laboratory Information Management System
DSM Launches Three Times Faster-acting Form of Vitamin D Supplement in Australia to Support Immune Health
Ipsen Announces New Data from the Phase II CLARINET FORTE Study

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  RightITnow, Inc.





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)